CAJ | 학술논문

目的:观察早期应用辛伐他汀强化治疗对急性冠状动脉综合征(ACS)患者血小板氧化低密度脂蛋白内皮受体-1(LOX-1)表达和近期预后的影响.方法:87例ACS患者随机分为A、B组, A组患者在常规药物治疗基础上早期给予辛伐他汀20 mg/晚,B组患者在常规药物治疗基础上早期给予辛伐他汀60 mg/晚,入院后次日及1周后采血检测肝肾功能、血糖、血脂、血小板聚集功能、血小板LOX-1的表达,观察入院后30 d内主要心血管事件.结果:治疗后2组患者血小板LOX-1水平均有明显下降,B组下降更明显,2组比较差异有统计学意义 (2.91±0.65∶2.61±0.51,P<0.05).治疗后2组患者血小板聚集功能均有明显下降,B组降低更明显,2组比较差异有统计学意义(34.2±11.1∶29.4±7.7,P<0.05).B组较A组30 d内主要心血管事件发生更低.结论:早期强化他汀类药物治疗ACS患者短期内能抑制血小板功能,改善患者的近期预后,这可能与抑制血小板LOX-1的表达有关.
목적:관찰조기응용신벌타정강화치료대급성관상동맥종합정(ACS)환자혈소판양화저밀도지단백내피수체-1(LOX-1)표체화근기예후적영향.방법:87례ACS환자수궤분위A、B조, A조환자재상규약물치료기출상조기급여신벌타정20 mg/만,B조환자재상규약물치료기출상조기급여신벌타정60 mg/만,입원후차일급1주후채혈검측간신공능、혈당、혈지、혈소판취집공능、혈소판LOX-1적표체,관찰입원후30 d내주요심혈관사건.결과:치료후2조환자혈소판LOX-1수평균유명현하강,B조하강경명현,2조비교차이유통계학의의 (2.91±0.65∶2.61±0.51,P<0.05).치료후2조환자혈소판취집공능균유명현하강,B조강저경명현,2조비교차이유통계학의의(34.2±11.1∶29.4±7.7,P<0.05).B조교A조30 d내주요심혈관사건발생경저.결론:조기강화타정류약물치료ACS환자단기내능억제혈소판공능,개선환자적근기예후,저가능여억제혈소판LOX-1적표체유관.
Objective:To observe the effect of early intensified use of simvastatin treatment on platelet oxidized low-density lipoprotein receptor-1( LOX-1) expression and short-term prognosis, in patients with acute coronary syndrome. Method:Eighty-seven cases with ACS were randomly divided into A, B group, Patients in A group based on conventional drug therapy was given simvastatin 20 mg/night, patients in B group based on conventional drug therapy was given simvastatin 60 mg/night Blood liver and kidney function, blood sugar, blood lipids, platelet aggregation, platelet expression of LOX-1 was tested on the first day after admission and the day after a week, major cardiovascular events was observed within 30 days after admission.Result:After a week, both groups have decreased platelet aggregation, B group reduced more significantly than A group (34.2±11.1 vs 29.4±7.7,P＜0.05). The platelet LOX-1 levels were significantly decreased in two groups after treatment too, B group decreased more significantly(2.91±0.65 vs 2.61±0.51,P＜0.05). Major cardiovascular events within 30 days after admission occurred less in group B.Conclusion:The early intensive simvastatin therapy in patients with acute coronary syndrome can inhibit platelet function and improve short-term prognosis of patients, it may work by inhibiting platelet LOX-1 expression.